HC Wainwright Predicts Kodiak Sciences Q2 Earnings

Kodiak Sciences Inc. (NASDAQ:KOD - Free Report) - HC Wainwright issued their Q2 2025 earnings estimates for Kodiak Sciences in a report issued on Monday, March 31st. HC Wainwright analyst M. Caufield forecasts that the company will earn ($0.99) per share for the quarter. HC Wainwright currently has a "Neutral" rating and a $3.00 target price on the stock. The consensus estimate for Kodiak Sciences' current full-year earnings is ($3.45) per share. HC Wainwright also issued estimates for Kodiak Sciences' Q3 2025 earnings at ($1.10) EPS, Q4 2025 earnings at ($1.23) EPS, FY2025 earnings at ($4.23) EPS, FY2026 earnings at ($4.63) EPS, FY2027 earnings at ($4.10) EPS and FY2028 earnings at ($2.90) EPS.

Separately, Jefferies Financial Group upgraded Kodiak Sciences from a "hold" rating to a "buy" rating and set a $20.00 price objective for the company in a research note on Monday, December 9th.

Kodiak Sciences Trading Down 3.4 %

NASDAQ:KOD traded down $0.08 during midday trading on Thursday, reaching $2.11. The company had a trading volume of 137,761 shares, compared to its average volume of 342,744. Kodiak Sciences has a 12-month low of $2.04 and a 12-month high of $11.60. The firm has a market capitalization of $111.03 million, a price-to-earnings ratio of -0.58 and a beta of 2.40. The stock's fifty day simple moving average is $4.22 and its 200-day simple moving average is $5.44.

Kodiak Sciences (NASDAQ:KOD - Get Free Report) last issued its quarterly earnings results on Thursday, March 27th. The company reported ($0.84) EPS for the quarter, beating the consensus estimate of ($0.90) by $0.06.

Hedge Funds Weigh In On Kodiak Sciences

Several large investors have recently bought and sold shares of the business. PNC Financial Services Group Inc. boosted its position in shares of Kodiak Sciences by 1,501.5% during the 4th quarter. PNC Financial Services Group Inc. now owns 3,187 shares of the company's stock worth $32,000 after acquiring an additional 2,988 shares in the last quarter. American Century Companies Inc. boosted its holdings in Kodiak Sciences by 6.2% in the fourth quarter. American Century Companies Inc. now owns 59,967 shares of the company's stock valued at $597,000 after purchasing an additional 3,515 shares in the last quarter. US Bancorp DE purchased a new position in Kodiak Sciences in the fourth quarter valued at approximately $40,000. Bank of New York Mellon Corp raised its holdings in Kodiak Sciences by 5.3% during the fourth quarter. Bank of New York Mellon Corp now owns 98,102 shares of the company's stock worth $976,000 after purchasing an additional 4,927 shares in the last quarter. Finally, Northern Trust Corp lifted its position in shares of Kodiak Sciences by 2.9% during the 4th quarter. Northern Trust Corp now owns 269,597 shares of the company's stock worth $2,682,000 after buying an additional 7,678 shares during the last quarter. Hedge funds and other institutional investors own 89.06% of the company's stock.

Kodiak Sciences Company Profile

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.